On April 13, 2020 BroadenBio reported that in March 2020, the company has completed the Angel+ round financing from Beijing Kaiyuan Hongdao Venture Capital Center (L.P.) (Kaiyuan Hongdao Fund) (Press release, BroadenBio, APR 13, 2020, View Source [SID1234640196]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kaiyuan Hongdao Fund is an industry-finance linkage investment fund established by Beijing Zhongguancun Venture Capital Development Co., Ltd., and its investment fields involve medical devices, biomedicine, and security payments.